AAP
KPTI icon

Ardsley Advisory Partners’s Karyopharm Therapeutics KPTI Stock Holding History

Ardsley Advisory Partners’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-700
Closed -$179K – 129
2018
Q3 		$179K Sell
700
-667
-49% -$184K 0.02% 140
2018
Q2 		$348K Buy
+1,367
New +$338K 0.05% 130

Other funds holding KPTI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCI
Ridgeback Capital Investments Miami Beach, Florida $560K AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ardsley Advisory Partners's KPTI Position: Q4 2018 in Review

Ardsley Advisory Partners sold out of Karyopharm Therapeutics (KPTI) in Q4 2018, closing a stake of 700 shares — an estimated $179K sold.

Ardsley Advisory Partners first reported a position in KPTI in Q2 2018 and held it in 2 quarters. The position peaked at $348K in Q2 2018. 115 funds tracked by Wall St. Rank hold KPTI as of Q4 2018.

  • Ardsley Advisory Partners reported no remaining Karyopharm Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Ardsley Advisory Partners sold 700 Karyopharm Therapeutics shares in Q4 2018, an estimated $179K.
  • Ardsley Advisory Partners first reported a position in Karyopharm Therapeutics in Q2 2018 and held it in 2 quarters.
  • Ardsley Advisory Partners's Karyopharm Therapeutics position peaked at $348K in Q2 2018.
  • 115 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2018.

Based on Ardsley Advisory Partners's 13F filing for Q4 2018, filed 14 Feb 2019.